Lexicon to present 52-week data on dual SGLT1 and SGLT2 blocker at EASD

27 September 2018

Texan drugmaker Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced details of clinical data for oral diabetes therapy sotagliflozin, to be presented at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD).

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, is under investigation for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes.

Lexicon is collaborating with French drug major Sanofi (Euronext: SAN) on the therapy, under the terms of a 2015 deal that included an upfront payment of $300 million to the American firm, with the potential for up to $1.4 billion in regulatory and sales milestones.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK